PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis

Biochemical Journal

Volumn 386, Issue 1, 2005, Pages 119-125

  Muñoz Gámez, José Antonio ^a   Martín Oliva, David ^a   Aguilar Quesada, Rocío ^b   Cañuelo, Ana ^c   Nuñez, M Isabel ^d   Valenzuela, M Teresa ^a   Ruiz De Almodovar J M ^d   De Murcia, Gilbert ^e   Oliver, F Javier ^b  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^c UNIVERSITY OF JAÉN   (Spain)

^d UNIVERSITY OF GRANADA   (Spain)

^e Cancerogenese Mutagenese Molec S   (France)

Author keywords

Apoptosis; Bax; Breast cancer; Chemotherapy; Doxorubicin; Mitochondria; p53; Poly(ADP ribose) polymerase 1 (PARP 1)

Indexed keywords

BIOCHEMISTRY; CELLS; DNA; FLUORESCENCE; IMMUNOLOGY; TUMORS;

BREAST CANCER; DNA REPAIR; IMMUNOFLUORESCENCE; POLYMERASE;

ENZYME INHIBITION;

4 AMINO 1,8 NAPHTHALIMIDE; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CASPASE; CASPASE 3; CYTOCHROME C; DOXORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BAX; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ASSAY; COLONY FORMING CELL; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SELECTIVITY; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; TARGET CELL; WESTERN BLOTTING;

1-NAPHTHYLAMINE; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CASPASE 3; CASPASES; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GENES, P53; HUMANS; INTRACELLULAR MEMBRANES; MEMBRANE POTENTIALS; MITOCHONDRIA; NAPHTHALIMIDES; NEOPLASM PROTEINS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINOLONES; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 14244258961     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20040776     Document Type: Article

References (23)

1. Johnstone, R. W., Ruefli, A. A. and Lowe, S. W. (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell (Cambridge, Mass.) 108, 153-164
2. Shin, M. S., Kim, H. S., Lee, S. H., Park, W. S., Kim, S. Y., Park, J. Y., Lee, J. H., Lee, S. K., Lee, S. N., Jung, S. S. et al. (2001) Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. 61, 4942-1946
3. Geisler, S., Lonning, P. E., Aas, T., Johnsen, H., Fluge, O., Haugen, D. F., Lillehaug, J. R., Akslen, L. A., and Borresen-Dale, A. L. (2001) Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer: prognostic significance of apoptosis regulators in breast cancer. Cancer Res. 61, 2505-2512
4. Krajewski, S., Krajewska, M., Turner, B. C., Pratt, C., Howard, B., Zapata, J. M., Frenkel, V., Robertson, S., Ionov, Y., Yamamoto, H. et al. (1999) Prognostic significance of apoptosis regulators in breast cancer. Endocr. Relat. Cancer 6, 29-40
5. Makin, G. and Dive, C. (2001) Apoptosis and cancer chemotherapy. Trends Cell Biol. 11, S22-S26
6. Shall, S. and de Murcia, G. (2000) Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat. Res. 460, 1-15
7. Miknyoczki, S. J., Jones-Bolin, S., Pritchard, S., Hunter, K., Zhao, H., Wan, W., Ator, M., Bihovsky, R., Hudkins, R., Chatterjee, S., Klein-Szanto, A. et al. (2003) Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther. 2, 371-382
8. Schlicker, A., Peschke, P., Burkle, A., Hahn, E. W. and Kim, J. H. (1999) 4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer. Int. J. Radiat. Biol. 75, 91-100
9. Ruiz-Ruiz, M. C. and Lopez-Rivas, A. (1999) p53-mediated up-regulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells. Cell Death. Differ. 6, 271-280
10. Ostrakhovitch, E. A. and Cherian, M. G. (2004) Differential regulation of signal transduction pathways in wild type and mutated p53 breast cancer epithelial cells by copper and zinc. Arch. Biochem. Biophys. 423, 351-361
11. Valenzuela, M. T., Nunez, M. I., Villalobos, M., Siles, E., Olea, N., Pedraza, V., McMillan, T. J. and Ruiz de Almodovar, J. M. (1995) Relationship between doxorubicin cell sensitivity, drug-induced DNA double-strand breaks, glutathione content and P-glycoprotein in mammalian tumor cells. Anti-Cancer Drugs 6, 749-757
12. Xie, Q. W., Kashiwabara, Y. and Nathan, C. (1994) Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J. Biol. Chem. 269, 4705-4708
13. Martin-Oliva, D., O'Valle, F., Munoz-Gamez, J. A., Valenzuela, M. T., Nunez, M. I., Aguilar, M., Almodovar, J. R., Moral, R. G. and Oliver, F. J. (2004) Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia. Oncogene 23, 5275-5283
14. Oliver, F. J., Menissier-de Murcia, J., Nacci, C., Decker, P., Andriantsitohaina, R., Muller, S., de la Rubia, G., Stoclet, J. C. and de Murcia, G. (1999) Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J. 18, 4446-4454
15. Banasik, M., Komura, H., Shimoyama, M. and Ueda, K. (1992) Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J. Biol. Chem. 267, 1569-1575
16. Lin, A. and Karin, M. (2003) NF-kappaB in cancer: a marked target. Semin. Cancer Biol. 13, 107-114
17. Pratt, M. A., Bishop, T. E., White, D., Yasvinski, G., Menard, M., Niu, M. Y. and Clarke, R. (2003) Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol. Cell. Biol. 23, 6887-6900
18. de Almodovar, C. R., Ruiz-Ruiz, C., Rodriguez, A., Ortiz-Ferron, G., Redondo, J. M. and Lopez-Rivas, A. (2004) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site. J. Biol. Chem. 279, 4093-1101
19. Gudkov, A. V., Zelnick, C. R., Kazarov, A. R., Thimmapaya, R., Suttle, D. P., Beck, W. T. and Roninson, I. B. (1993) Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc. Natl. Acad. Sci. U.S.A. 90, 3231-3235
20. Virag, L. and Szabo, C. (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54, 375-429
21. Mendeleyev, J., Kirsten, E., Hakam, A., Buki, K. G. and Kun, E. (1995) Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem. Pharmacol. 50, 705-714
22. Bowman, K. J., Newell, D. R., Calvert, A. H. and Curtin, N. J. (2001) Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br. J. Cancer 84, 106-112
23. Pacher, P., Liaudet, L., Bai, P., Virag, L., Mabley, J. G., Hasko, G. and Szabo, C. (2002) Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J. Pharmacol. Exp. Ther. 300, 862-867